4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
Cystic Fibrosis Foundation to provide up to $11 million in additional funding to accelerate development of 4D-710 for cystic fibrosis,...
Staff
Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors
Appointment adds three decades of financial and operational leadership to Soleno’s BoardREDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) --...
Connect Appoints Tre Braquet as Chief Brand & Engagement Officer
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Connect, a premier nonprofit organization in San Diego’s innovation ecosystem dedicated to...
Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings
- VCN-01 expanded mPDAC data from VIRAGE Phase 2b trial to be presented at ESMO 2025 - - SYN-004 Interim...
Immutep Announces Successful Completion of FDA Project Optimus Requirements
Confirmation of 30mg efti as optimal biological dose relevant for Immutep’s oncology pipeline and potential future Biological License Applications (BLA)Registrational...
Apyx Medical Corporation Submits FDA 510(k) for Device Label Expansion of AYON Body Contouring System™ for Power Liposuction
Initiated Nationwide Commercial Launch of AYON in September The Company is Hosting a Virtual Key Opinion Leader Event to Discuss...
Stereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias
ST. LOUIS and MARLBOROUGH, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in...
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
Designation supported by results from multiple dose cohorts from the Phase 1/1b trial of ficerafusp alfa in 1L HPV-negative R/M...
BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025
Biomarkers identified in Phase 2 study demonstrate similar trends in ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast...
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
Second year proceeds granted following FDA review of annual performance progress report on Phase 3 SELVA single-arm, baseline-controlled trial; up...
Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program
RDEA Pilot Program provides sponsors enhanced communication and collaboration with FDA to accelerate development of rare disease therapiesCLEVELAND, Oct. 13,...
Kraig Biocraft Laboratories Announces Selective Breeding Advancement, Significantly Increasing Both Spider Silk Production Throughput and Hybrid Vigor
ANN ARBOR, Mich., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company", “Kraig” or "Kraig Labs"),...
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
– Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn.,...
Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events
CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and...
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
FRIENDSWOOD, Texas, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests...
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation
NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use...
Together We Build: Rentschler Biopharma celebrates construction progress of new buffer media facility, largest single investment at Laupheim site
Symbolic milestone for new buffer media station: Rentschler Biopharma underscores its commitment to the Laupheim headquarters and to the future of...
Artios to Announce First Phase 1/2a Data for DNA Polymerase Theta (Polθ) Inhibitor ART6043 in Advanced Solid Tumors in Oral Presentation at ESMO
CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the...
CHAPPER healthcare, AscellaHealth’s Global Pharmaceutical Distributor, Celebrates 50 Years of Global Pharmaceutical Excellence
This milestone marks half a century of innovation, reliability and access to life-saving medicines worldwideWATFORD, United Kingdom and BERWYN, Pa.,...
Immuron Q1 FY26 YoY growth
Sales Highlights (unaudited): Global•Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp) Australia•Q1 sales AUD$1.6 million up 52% on...